Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.

Autor: Comabella M; Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)-ISCIII, Madrid, Spain., Hegen H; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Villar LM; Departments of Neurology and Immunology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigacion Sanitaria, Madrid, Spain., Rejdak K; Department of Neurology, Medical University of Lublin, Lublin, Poland., Sao-Avilés A; Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Behrens M; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Sastre-Garriga J; Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Mongay N; Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Berek K; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria., Martínez-Yelamos S; Department of Neurology, Bellvitge University Hospital, Barcelona, Spain., Pérez-Miralles F; Neuroimmunology Unit, València University and Polytechnic Hospital La Fe, València, Spain., Abdelhak A; Department of Neurology, Ulm University, Ulm, Germany.; Division of Neuroinflammation and Glial Biology, Department of Neurology, University of California San Francisco, San Francisco, USA., Bachhuber F; Department of Neurology, Ulm University, Ulm, Germany., Tumani H; Department of Neurology, Ulm University, Ulm, Germany., Lycke J; Fundación INCE (Iniciativa Para Las Neurociencias), Madrid, Spain., Carbonell-Mirabent P; Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Valls-Carbó A; Fundación INCE (Iniciativa Para Las Neurociencias), Madrid, Spain., Rosenstein I; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Alvarez-Lafuente R; Environmental Factors in Degenerative Diseases Research Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain., Castillo-Triviño T; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)-ISCIII, Madrid, Spain.; Neurology Department, Hospital Universitario Donostia, San Sebastián, Spain., Otaegui D; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)-ISCIII, Madrid, Spain.; Multiple Sclerosis Unit, Biodonostia Health Research Institute, San Sebastián, Spain., Llufriu S; Neuroimmunology and Multiple Sclerosis Unit, Service of Neurology, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain., Blanco Y; Neuroimmunology and Multiple Sclerosis Unit, Service of Neurology, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain., Sánchez-López AJ; Neuroimmunology Unit, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain.; Biobank, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain., García-Merino A; Neuroimmunology Unit, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain., Fissolo N; Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.; Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)-ISCIII, Madrid, Spain., Gutiérrez L; Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Villacieros-Álvarez J; Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Monreal E; Department of Neurology, Hospital Universitario Ramón y Cajal, REEM, IRYCIS, Universidad de Alcalá, Madrid, Spain., Wiendl H; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Montalban X; Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Lünemann JD; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany. Jan.Luenemann@ukmuenster.de.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2024 Dec 12; Vol. 272 (1), pp. 26. Date of Electronic Publication: 2024 Dec 12.
DOI: 10.1007/s00415-024-12763-w
Abstrakt: Background and Objectives: The impact of viral infections on disease susceptibility and progression has predominantly been studied in patients with relapse-onset MS (RMS). Here, we determined immune responses to ubiquitous viruses in patients with primary progressive MS (PPMS).
Methods: Antibody responses to Epstein-Barr virus (EBV), specifically to the latent EBV nuclear antigen 1 and the lytic viral capsid antigen VCA, human herpesvirus 6 (HHV-6), human cytomegalovirus (HCMV), and measles virus were determined in a cohort of 68 PPMS patients with a mean follow-up of 8 years and compared with 66 healthy controls matched for sex and age.
Results: Compared with controls, PPMS patients showed increased humoral immune responses to the EBV-encoded nuclear antigen-1 (EBNA1), but not to the lytic EBV capsid antigen (VCA) or to other viral antigens. Seroprevalence rates for HCMV were significantly higher in PPMS. Antiviral immune responses at baseline did not correlate with disability progression over time.
Discussion: Elevated immune responses toward EBNA1 are selectively increased in people with primary progressive disease, indicating a link between EBNA1-targeting immune responses and the development of both RMS and PPMS. Our data also suggest that chronic HCMV infection is associated with progressive MS.
Competing Interests: Declarations. Conflicts of interest: The authors declare that they have no competing interests to declare that are relevant to the content of this article.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: